Advanced Filters
noise

pulmonary-arterial-hypertension Clinical Trials

A listing of pulmonary-arterial-hypertension medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 83 clinical trials
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

Natural History Study of Biomarkers in Pulmonary Arterial Hypertension

Background High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover …

18 - 100 years of age Both Phase N/A
K Kelly Burke, RN

Risk and Resilience in Pulmonary Arterial Hypertension and Genetically Susceptible Individuals

Pulmonary arterial hypertension (PAH) is a severe disease with a delayed diagnosis and markedly elevated mortality. High-risk populations, such as those with known genetic defects, provide a unique opportunity to determine the features of susceptibility and resilience to PAH. This proposal will fundamentally overturn the prevailing understanding of PAH by …

15 - 80 years of age Both Phase N/A
G Guido Claessens, MD, PhD

Validation of a Machine Learning Predictive Model to Distinguish Post-capillary Pulmonary Hypertension

In this study the diagnostic accuracy of a diagnostic tool for the diagnosis of post-capillary pulmonary hypertension will be investigated. The diagnostic tool was designed based on artificial intelligence, using machine learning on a database of 344 patients with group 1 or group 2 pulmonary hypertension. The tool uses 20 …

18 - 100 years of age Both Phase N/A

Multi-marker Approach for Risk Assessment in PAH

Prospective registry including incident patients and prevalent patients which pretends to identify clinical characteristics, treatment trends in-hospital and ten years follow-up outcome through major adverse cardiovascular events (MACE) in a China population with well characterized PAH.

1 - 85 years of age Both Phase N/A
A Arun Jose, MD, MS

HRV as a Marker of Treatment Response in PAH Arterial Hypertension

This is a prospective longitudinal cohort study to determine the value of HRV obtained using noninvasive actigraphy to quantify the response to pulmonary vasodilator therapy in newly diagnosed PAH patients

18 - 70 years of age Both Phase N/A
D David Owen, MD PhD

Quantifying 18kDa TSPO Expression in the Lung in Pulmonary Artery Hypertension (PAH)

The aim of this study is to determine whether there is an increase in the TSPO PET signal (measured with the radioligand [11C]PBR28) in the lungs of patients living with PAH relative to age matched controls. If so, TSPO PET may be a useful technique to non-invasively monitor response to …

25 - 75 years of age Both Phase N/A
S Stefano Ghio, PI

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

The PROMPTLY study is a proof-of-concept research project evaluating the efficacy of XHALIP, an innovative inhalable formulation of Imatinib, in treating pulmonary arterial hypertension (PAH) and post-inflammatory fibrosing lung diseases (LFD). Main Objective To demonstrate the ability of XHALIP to improve the prognosis of PAH and LFD by reducing pulmonary …

18 - 100 years of age Both Phase N/A
P Paul Hassoun, MD

Cardiac Assessment by PV Loop in IPAH and Scleroderma PAH

This observational study is being done to understand why people with scleroderma can develop pulmonary arterial hypertension (high blood pressure in the lungs, abbreviated PAH) and a weak heart muscle (heart failure). The study will also help the investigators understand why people with PAH from an unknown cause (called idiopathic …

18 - 100 years of age Both Phase N/A
J Jiapeng Huang, MD, PhD

Study Roles of Heavy Metals and Essential Metal Dyshomeostasis in Pulmonary Arterial Hypertension Patients

Investigators plan to recruit 50 PAH patients from UofL PAH Clinic, with various degrees of severity (25 intermediate risk patients and 20 high risk patients) and 10 age and gender matched controls. PAH patients are evaluated at least every 6 months by the PAH Clinic and blood/urine samples will be …

18 - 100 years of age Both Phase N/A
L Luigi R Boccardi, BS

Pulmonary Hypertension Biorepository and Registry

Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.

18 - 100 years of age Both Phase N/A

Rewrite in simple language using AI